We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




DNA Blood Test Increases Targeted Treatment Access

By LabMedica International staff writers
Posted on 20 Jun 2013
A molecular blood test for women with breast cancer could identify more women who will benefit from the targeted drug treatment with Herceptin, without the need for uncomfortable biopsies.

The blood test is a liquid biopsy that uses cutting-edge genetic techniques to detect breast cancer DNA in the bloodstream and can detect whether breast cancers are being driven by too many copies of the Human Epidermal Growth Factor Receptor 2 (HER2) gene. More...


Scientists at The Institute of Cancer Research (London, UK) obtained 58 blood samples from a consecutive prospective series of patients with metastatic breast cancer treated at the Royal Marsden Hospital (London, UK) between 2010 and 2012. They used microarray comparative genomic hybridization data from 311 invasive breast cancers, 65 HER2-amplified, and 246 HER2-nonamplified to identify an optimal chromosome 17 copy number reference region.

The digital polymerase chain reaction (dPCR) was performed in 384-well format with 360 well for sample assessment and 24 wells of negative control prepared without the addition of sample DNA. The dPCR was performed on the X100 droplet PCR system (Bio-Rad; Hercules, CA, USA). The results showed substantially higher concordance with tumor-derived HER2 status compared with prior reports of noninvasive approaches.

The new technique was able to accurately identify HER2-positive breast cancer in 7/11 (64%) of the patients, 44 of 47 (94%) were classified as plasma DNA digital PCR HER2-negative. This gives a positive predictive value of 70% and negative predictive value of 92%. The authors concluded that the analysis of plasma DNA with digital PCR has the potential to screen for the acquisition of HER2 amplification in metastatic breast cancer. This approach could potentially be adapted to the analysis of any locus amplified in cancer.

Alan Ashworth, PhD, FRS, CEO of the Institute of Cancer Research, said, “This new liquid biopsy has exciting potential as a means of analyzing tumor DNA in the blood stream, allowing clinicians to track genetic changes as they happen and adjust treatment to them. By assessing quickly and painlessly whether a particular gene is activated in breast cancer, doctors will be able to choose the best targeted therapy for their patients.” The study was published on May 1, 2013, in the journal Clinical Cancer Research.

Related Links:
The Institute of Cancer Research
Royal Marsden Hospital
Bio-Rad


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.